Agile Therapeutics Revenue 2013-2023 | AGRX

Agile Therapeutics revenue from 2013 to 2023. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Agile Therapeutics Annual Revenue
(Millions of US $)
2023 $20
2022 $11
2021 $4
2020 $1
2019 $
2018 $
2017 $
2016 $
2015 $
2014 $
2013 $
2012 $
Agile Therapeutics Quarterly Revenue
(Millions of US $)
2023-12-31 $4
2023-09-30 $7
2023-06-30 $6
2023-03-31 $4
2022-12-31 $4
2022-09-30 $3
2022-06-30 $2
2022-03-31 $2
2021-12-31 $2
2021-09-30 $1
2021-06-30 $1
2021-03-31 $0
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2014-06-30
2014-03-31
2013-12-31
2013-09-30
2013-06-30
2012-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.003B $0.020B
Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. It is focused on the development and commercialization of new prescription contraceptive products. The Company's lead product candidate is Twirla (TM), also known as AG200-15, a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Agile Therapeutics, Inc. is headquartered in Princeton, New Jersey.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $14.328B 5.17
Dr Reddy's Laboratories (RDY) India $11.833B 18.71
Aspen Pharmacare (APNHY) South Africa $5.172B 0.00
BridgeBio Pharma (BBIO) United States $4.387B 0.00
Bausch Health Cos (BHC) Canada $3.143B 2.45
Amphastar Pharmaceuticals (AMPH) United States $1.889B 12.93
Supernus Pharmaceuticals (SUPN) United States $1.580B 0.00
Taysha Gene Therapies (TSHA) United States $0.451B 0.00
Generation Bio (GBIO) United States $0.185B 0.00
Assembly Biosciences (ASMB) United States $0.073B 0.00
Personalis (PSNL) United States $0.061B 0.00
Acasti Pharma (ACST) Canada $0.029B 0.00
Sol-Gel Technologies (SLGL) Israel $0.025B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00